Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes

By R. Bonnet. Antimicrobial Agents and Chemotherapy, 2004

1,684 citations recorded by the source corpus.

Subfields: Molecular Medicine, Pharmacology, Pollution

View Paper: https://www.semanticscholar.org/paper/b122e2a46cdefbed65ea9ae971fb09f4eedb02cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Medicine

1. P. Nordmann
2. K. Bush
3. L. Poirel
4. P. Bradford
5. J. Pitout
6. Robert A. Bonomo
7. G. Jacoby
8. Sarah M. Drawz

In Pharmacology

1. P. Nordmann
2. L. Poirel
3. P. Bradford
4. J. Pitout
5. Barry G. Hall
6. Robert A. Bonomo
7. K. Bush
8. Miriam Barlow

In Pollution

1. P. Nordmann
2. L. Poirel
3. K. Bush
4. J. Pitout
5. Barry G. Hall
6. Robert A. Bonomo
7. P. Bradford
8. Miriam Barlow

Citations in the corpus

• CTX-M Enzymes: Origin and Diffusion (2012, background): “Although different updates about CTX-M β-lactamases have been published (Bonnet, 2004; Livermore et al., 2007; Rossolini et al., 2008; Hawkey and Jones, 2009; Naseer and Sundsfjord, 2011), new data about dispersion and clonality of CTX-M producing isolates, molecular epidemiology, protein…”
• Epidemiology of β-Lactamase-Producing Pathogens (2020, background): “The CTX-M-type enzymes can be phylogenetically divided into five distinct clusters in which the group members share 94% identity (in contrast, 90% identity is observed between the members belonging to the other groups) (154).”
• Updated Functional Classification of β-Lactamases (2009, background): “TEM and SHV ESBLs have been joined by the functionally similar but more rapidly proliferating CTX-M enzymes that are related to chromosomally determined -lactamases in species of Kluyvera (8).”
• Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. (2015, background): “Extendedspectrum b-lactamases (ESBLs) mediate resistance to all penicillins, third generation cephalosporins (e.g. ceftazidime, cefotaxime, and ceftriaxone) and aztreonam, but not to cephamycins (cefoxitin and cefotetan) and carbapenems (Bonnet, 2004).”
• Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. (2007, background): “This phenomenon coincided with the emergence of a new group of plasmid-mediated ESBLs, namely the CTX-M enzymes, which seem to be taking over as the main ESBL type in some locales.(3,4) Multiple locales are encountering CTX-M-positive E.”
• Action and resistance mechanisms of antibiotics: A guide for clinicians (2017, neutral): “, clavulanic acid, sulbactam, or tazobactam[21-23] b.”
• Evolution of the serine β-lactamases: past, present and future (2004, background): “The first CTX-M enzyme was isolated in 1986, and over the next 9 years only an additional four members of that family were isolated (Bonnet, 2004) (see Bonnet, 2004 for a recent review of the CTX-M enzymes).”
• Three Decades of β-Lactamase Inhibitors (2010, background): “are nonpathogenic commensal organisms (14, 32).”
• Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. (2005, background): “For Permissions, please e-mail: journals.permissions@oupjournals.org reports from Europe, Africa, Asia, South America and North America.10 Other rare types of ESBLs include the GES/IBC, VEB and PER b-lactamases.11–13 The VEB enzymes are widely distributed in Enterobacteriaceae from South East Asia11”